Alnylam Pharmaceuticals shares rose 10% Friday after the company nabbed FDA approval to sell its drug Amvuttra to a larger ...

US stocks end up with S&P 500 and Dow gaining on the week. Focus returns to the economy and tariffs. FedEx and Nike fall ...

Alnylam Pharmaceuticals gains FDA approval for Amvuttra in ATTR-CM, boosting revenue prospects. Click here to read an ...

Alnylam Pharma (ALNY) stock rocketed higher on Friday after the pharmaceutical company received approval from the U.S. Food and Drug ...

Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Alnylam Pharmaceuticals's whale activity within a strike price range from $210.0 to $340 ...

Amvuttra is now approved in the US to treat both cardiomyopathy and polyneuropathy manifestations of ATTR amyloidosis.

ALNY secures FDA approval for an sNDA in the United States, seeking the label expansion of Amvuttra to treat ATTR amyloidosis with cardiomyopathy.

Alnylam stock jumped Friday after the drugmaker won a second Food and Drug Administration approval for its drug, Amvuttra.

This expanded indication for Amvuttra makes it the first and only FDA-approved treatment for transthyretin amyloidosis with ...

Key health developments include the White House considering Michael Burgess for CDC leadership, rising measles cases in Texas ...

The FDA's approval of Alnylam's heart disease drug expands treatment options in a market poised for growth. Meanwhile, the ...

Alnylam will likely face challenges in turning a profit this year, despite executives promising to do so. But the label for ...